Proactiveinvestors United Kingdom Sativa Group PLC https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom Sativa Group PLC RSS feed en Fri, 19 Jul 2019 06:53:36 +0100 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[News - Sativa in talks with beverage firms to create CBD drinks in the UK ]]> https://www.proactiveinvestors.co.uk/companies/news/223445/sativa-in-talks-with-beverage-firms-to-create-cbd-drinks-in-the-uk-223445.html Cannabis firm Sativa Group PLC (NEX:SATI) is in talks with beverage companies to make cannabidiol (CBD) drinks for UK consumers. 

The company’s manufacturing and distribution business, George Botanicals, has created a water-soluble CBD emulsion that can be added to food and drinks.

Geremy Thomas, the chief executive of Sativa, told Proactive Investors he has been in discussions with beverage companies he could not name yet to incorporate the emulsion into drinks.

READ: Sativa says 2019 first quarter revenues exceeding total revenues in the group’s first year of trading

“CBD products are mainly oil based but putting oils in water is difficult so we’ve made an emulsion that we can sell into the food and drinks industry,” he said.

Thomas expects the company to see a “big revenue uptick” from the new CBD products George Botanicals is developing.

George Botanicals' products currently include oils, balms, capsules and liquid additives for e-cigarettes.

The products are available online and at Sativa’s newly opened CBD retail store, Goodbody Wellness, in Bath.  

Sativa to roll out 100 CBD wellness stores 

Sativa opened the Bath store last Friday evening and plans to open 100 stores in the next two years. The next two stores will be opened in Cirencester and Bristol.

Thomas said the Bath store has already experienced strong demand in its first week of operation.

READ: Sativa opens first CBD wellness store with trading ahead of expectations

“Customers really liked the experience and bought more than we thought they would and I think that’s very encouraging,” he said.

While the roll out of 100 stores in two years may seem like an ambitious target, Thomas sees an opportunity to tap into a market that is expected to be worth £300mln in the UK this year and £1bn by 2025.

Thomas said the company plans to use its advantage as the UK’s first medical cannabis firm and get ahead of the game before rivals enter the scene.

New name to reflect new strategy 

The company listed on the NEX exchange as Sativa Investments in 2017 but has since changed its name to Sativa Group to reflect a change in the business model in response to the legalisation of medicinal marijuana in the UK last November.

Sativa was formed as an investment vehicle that put money into other medicinal cannabis firms. But it has since transformed into a trading company with three UK businesses including George Botanicals, Goodbody Wellness and medicinal cannabis research facility PhytoVista Laboratories.

“We have three trading businesses that are growing fast and generating real revenues from real customers who are repurchasing our products because they are happy with it,” Thomas said.

Last month Sativa said revenue in the first quarter of 2019 had exceeded the amount generated in its first year of trading.

Thomas said the group has continued to trade strongly and is optimistic about delivering robust results for the full year.

“I’m an old fashioned businessman that likes to have revenue, customers and growth and that’s what we’ve been focusing on,” he said.

London 'waking up' to potential of cannabis market 

He admits the UK market still has a long way to go as doctors are still reluctant to prescribe medicinal cannabis to patients despite the change in rules.

However, he expects medicinal cannabis will become an “important and sizeable” sector in the UK given the growth seen in America, Canada and Germany as well as the fact that a number of companies have been looking to list in London. 

“The city is waking up to that and think we’ll see more and more quality companies coming to the market but we’re just keen to keep our first mover advantage in place,” he said.

He added: “There’s upward pressure from our patients, downward pressure from our senior politicians and the bit in the middle has to get their act together and that’s a process….but we’re seeing more and more progress.”

]]>
Fri, 05 Jul 2019 15:40:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/223445/sativa-in-talks-with-beverage-firms-to-create-cbd-drinks-in-the-uk-223445.html
<![CDATA[Media files - Sativa delighted with Cenkos appointment as it opens CBD wellness centre ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/13973/sativa-delighted-with-cenkos-appointment-as-it-opens-cbd-wellness-centre-13973.html Wed, 03 Jul 2019 12:41:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/13973/sativa-delighted-with-cenkos-appointment-as-it-opens-cbd-wellness-centre-13973.html <![CDATA[News - Sativa opens first CBD wellness store with trading ahead of expectations ]]> https://www.proactiveinvestors.co.uk/companies/news/223110/sativa-opens-first-cbd-wellness-store-with-trading-ahead-of-expectations-223110.html Sativa Group PLC (LON:SATI) opened its first cannabidiol (CBD) wellness retail outlet in Bath at the weekend and initial trading was ahead of expectations.

The Goodbody Wellness store was launched on Friday evening by Crispin Blunt, MP for Reigate and co-chair of the All Party Parliamentary Group for Drug Policy Reform.

READ: Sativa says 2019 first quarter revenues exceeding total revenues in the group’s first year of trading

Sativa said footfall, turnover and average transaction value in the first weekend of trading exceeded expectations. 

The store stocks more than 50 CBD products, including oils, vapes, skincare, tinctures, balms and capsules. It also sells CBD infused coffee and tea.

“Goodbody Wellness is the UK's first prestige CBD store and the Bath launch was a great success, with customer feedback being that the format is exactly what they wanted,” said Sativa chief executive Geremy Thomas.

He added: "Our product development and manufacturing capability allows multiple routes to market and the roll out of our Goodbody store network will drive revenues. 

“Bath is the first of three pilot stores after which the Company intends to roll-out a national franchise network, because the directors believe that this is the fastest and least capital-intensive route to a national footprint."  

]]>
Mon, 01 Jul 2019 08:17:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/223110/sativa-opens-first-cbd-wellness-store-with-trading-ahead-of-expectations-223110.html
<![CDATA[News - CBD oil brands contain little to no CBD, test by Sativa's UK lab reveals ]]> https://www.proactiveinvestors.co.uk/companies/news/222952/cbd-oil-brands-contain-little-to-no-cbd-test-by-sativa-s-uk-lab-reveals-222952.html Sativa Group PLC (NEX:SATI) subsidiary PhytoVista Laboratories has discovered instances of poor practice among producers of cannabidiol (CBD) products for the retail market.

The UK lab conducted a blind test of 30 major retail CBD oil brands for The Centre for Medicinal Cannabis.

CBD products contain little to no CBD 

The test found 38% of the products had less than 50% of the advertised CBD content. One product was completely free of CBD.

About 45% of the products contained measurable amounts of psychoactive cannabis compounds tetrahydrocannabinol (THC) and cannabinol (CBN). On average these products had 0.04% of THC and 0.01% of CBN.

Sativa said this means almost half of the products are “technically illegal”.

READ: Sativa says 2019 first quarter revenues exceeding total revenues in the group’s first year of trading

In November last year the UK legalised medicinal cannabis, which usually contains CBD and low levels of THC. However, only specialist doctors can prescribe the drug for certain ailments and only if other treatments have not worked.

THC produces the high people feel when smoking or ingesting marijuana while CBD is non-psychoactive, meaning it can be sold in the UK without a licence so long as claims are not made about any medical benefits.

Sativa said its test of the CBD products available at stores was “most revealing in terms of quality and instances of poor practice”.

It said the biggest issues related to accuracy of labelling, the presence of controlled substances and some contaminants.

One product had 3.8% ethanol while dichoromethane was detectable in seven products and cyclohexane was found in one product.

“These percentages of solvents and heavy metals are still below the permitted daily dose levels in pharmaceutical products, although above food limit safety levels,” Sativa said.

Sativa ensures checks on own CBD products 

The company said its CBD retail and wholesale business, George Botanicals, ensures that all of its products are tested by Phytovista.

The group added that its new CBD wellness store, Goodbody Wellness, which opens in Bath on Saturday, offers the same guarantee.

“Sativa identified early on that in established overseas markets for CBD, and in particular Canada, product testing and validation was an early stage bottleneck within the industry,” it said.

“PhytoVista is well established in the UK and has already conducted over 1500 independent tests."

]]>
Thu, 27 Jun 2019 12:35:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/222952/cbd-oil-brands-contain-little-to-no-cbd-test-by-sativa-s-uk-lab-reveals-222952.html
<![CDATA[News - Sativa says 2019 first quarter revenues exceeding total revenues in the group’s first year of trading ]]> https://www.proactiveinvestors.co.uk/companies/news/221974/sativa-says-2019-first-quarter-revenues-exceeding-total-revenues-in-the-groups-first-year-of-trading-221974.html Sativa Investments PLC (LON:SATI) has said its current financial year has begun well, with 2019 first quarter revenues exceeding total revenues in the group’s first year of trading.

In a brief trading statement to coincide with Wednesday’s annual general meeting, Geremy Thomas, founder and chief executive officer of the medicinal cannabis and wellness cannabidiol (CBD) group said: "Sativa is delivering real revenues in a new and exciting sector.  Key value drivers include manufacturing capability, testing, brands and distribution."

READ: Sativa Investments signs supply deal with Swiss cannabis oil producer Alponics

The Company also noted that, since the year-end, it has announced two overseas CBD oil take-off agreements, appointed RSM as auditor, appointed a Director of Regulatory Affairs and also a retail professional to oversee the roll-out of the Goodbody wellness centres, the first of which opens in Bath on 28 June 2019. 

In April 2019, the Company entered in to into a three-year research agreement with King's College London to research the impact of cannabinoids on inflammation and respiratory diseases.

The NEX-listed firm also said all resolutions were duly passed at today’s AGM including its proposed name change to Sativa Group PLC, which, now ratified by shareholders, will be completed within days.

]]>
Wed, 12 Jun 2019 12:51:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/221974/sativa-says-2019-first-quarter-revenues-exceeding-total-revenues-in-the-groups-first-year-of-trading-221974.html
<![CDATA[News - Sativa Investments signs supply deal with Swiss cannabis oil producer Alponics ]]> https://www.proactiveinvestors.co.uk/companies/news/221709/sativa-investments-signs-supply-deal-with-swiss-cannabis-oil-producer-alponics-221709.html Sativa Investments PLC (LON:SATI) has agreed a commercial offtake agreement with a Swiss supplier of cannabis oil for the manufacture of cannabidiol (CBD) products in the UK.

Under the three-year deal, Switzerland firm Alponics will supply Sativa with CBD distillate and isolate until the end of 2022.  

READ: Sativa Investments inks commercial offtake agreement with Portuguese cannabis oil supplier

Alponics, which was founded by Pacific Rim Plantation Services last year and has operations in Vaud and Valais, is expected to begin production this autumn.

"This commercial agreement with Alponics further advances our smart-sourcing strategy,” said Sativa founder and chief executive, Geremy Thomas.

"We look forward to a long and mutually beneficial relationship with Alan Chaytor and his impressive team."

Last month Sativa decided to abandon a plan to grow its own cannabis produce at a 7.5-acre Wiltshire site.

The company decided sourcing raw material would provide greater returns than growing its own supply.

As part of the new strategy, Sativa announced in late May that it had signed a commercial offtake agreement with Portuguese cannabis oil supplier, MeridianTulip – Empresa Medicinal Lda.

Sativa will acquire low tetrahydrocannabinol (THC) cannabis oil for the UK manufacturer of CBD products at its Somerset headquarters.

THC is a compound in the cannabis plant that gives the “high” associated with recreational use while CBD is non-psychoactive. Medicinal cannabis, which was legalised in the UK late last year, contains CBD and low levels of THC.

]]>
Fri, 07 Jun 2019 07:50:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/221709/sativa-investments-signs-supply-deal-with-swiss-cannabis-oil-producer-alponics-221709.html
<![CDATA[News - Sativa Investments inks commercial offtake agreement with Portuguese cannabis oil supplier ]]> https://www.proactiveinvestors.co.uk/companies/news/221019/sativa-investments-inks-commercial-offtake-agreement-with-portuguese-cannabis-oil-supplier-221019.html Sativa Investments PLC (NEX:SATI) has inked a commercial offtake agreement with Portuguese cannabis oil supplier, MeridianTulip – Empresa Medicinal Lda, for the UK manufacture of cannabidiol (CBD) products.

Under the deal, the UK medicinal cannabis company will acquire low tetrahydrocannabinol (THC) cannabis oil for the UK manufacturer of CBD products at its Somerset headquarters.

READ: Medicinal cannabis investor Sativa Investments turns maiden gross profit

THC is a compound in the cannabis plant that gives the “high” associated with recreational use while CBD is non-psychoactive. Medicinal cannabis, which was legalised in the UK late last year, contains CBD and low levels of THC.

Sativa plans to supply the cannabis products to its subsidiary George Botanicals, a manufacturer, wholesaler and retailer of CBD wellness products. It will also supply to Sativa’s Goodbody & Blunt wellness centres, which is to open its first store, in Bath, soon.  

The offtake agreement is subject to MeridianTulip receiving authority from Portuguese regulatory authority, Infarmed, for the cultivation and export of medicinal cannabis.

Sativa said Infarmed has granted two such licences to date and the company is confident Meridian’s discussions are “progressing well”.

“The offtake agreement with Meridian, once it receives its Infarmed licence, will provide clarity to a major part of the supply chain and give consistency across quality and pricing, as well as allowing the company to determine exact seed strains and growing conditions,” said Sativa founder and chief executive, Geremy Thomas.

“Yet again Sativa is at the forefront of this industry by identifying smart-sourcing as preferable to growing, as the company concentrates on the value-add elements of the industry, including research & development, manufacturing, brands, and distribution." 

]]>
Tue, 28 May 2019 07:59:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/221019/sativa-investments-inks-commercial-offtake-agreement-with-portuguese-cannabis-oil-supplier-221019.html
<![CDATA[News - Medicinal cannabis investor Sativa Investments turns maiden gross profit ]]> https://www.proactiveinvestors.co.uk/companies/news/220308/medicinal-cannabis-investor-sativa-investments-turns-maiden-gross-profit-220308.html Medicinal cannabis investor Sativa Investments PLC (NEX:SATI) turned a gross profit of £110,000 in 2018 – its first year as a listed company.

The company, which has investments in five cannabis companies around the world, joined the NEX Growth Market at the end of March last year.

In the 12 months to the end of December, Sativa reported turnover of £260,000, all of which came from its two UK ventures, George Botanicals and Phytovista.

READ: Sativa proposes name change

Gross profit for the period totalled £110,000, representing a gross margin of 42%.

The adjusted underlying loss (LBITDA) came in at £1.08mln, with the bulk of that relating to wages as Sativa builds a strong management team to drive future growth.

Among those to join is Alasdair Breckenridge, the former chairman of Medicines and Healthcare Products Regulatory Agency (MHRA), who now chairs Sativa’s medical advisory board.

A few fundraises during the course of the year has topped up the company’s coffers, with cash at hand ending the year at £3.74mln, which bosses said put them in a “strong position” to invest further into its businesses.

First wellness centre to open shortly

Looking ahead, Sativa is planning to open its first Goodbody & Blunt wellness centre in Bath in early summer.

The centre will sell a range of white label CBD products made by George Botanicals and other suppliers, all of which will be tested by Phytovista.

“Sativa has delivered expeditiously on its investment promise to the market and is now recognised as a trading business, with two fully owned UK subsidiaries already performing well,” said founder and chief executive Geremy Thomas.

“This early stage traction within the marketplace proves the Group's ability to deliver revenue-generating operations that benefit from first-mover advantage.”

He added: “The medicinal cannabis and CBD industries are highly complex and the twelve months of global research that I undertook before Sativa joined the NEX Exchange is paying off. Focussing on the high-margin value-add components of the seed to consumer chain is key, as is proximity to the end user.”

]]>
Wed, 15 May 2019 12:05:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/220308/medicinal-cannabis-investor-sativa-investments-turns-maiden-gross-profit-220308.html
<![CDATA[RNS press release - Final Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/16457/LSE20190515100223_14074838/ Wed, 15 May 2019 10:02:23 +0100 https://www.proactiveinvestors.co.uk/companies/rns/16457/LSE20190515100223_14074838/ <![CDATA[News - UK cannabis firm Sativa Investments proposes name change as it unveils new strategy ]]> https://www.proactiveinvestors.co.uk/companies/news/219857/uk-cannabis-firm-sativa-investments-proposes-name-change-as-it-unveils-new-strategy-219857.html UK medicinal cannabis firm Sativa Investments PLC (NEX:SATI) has decided to allow an option over a farm in Wiltshire to grow its own produce to lapse in July.

The company said it believes sourcing raw material will provide greater returns than growing its own supply.

Sativa signed the option on the 7.53 acre site in October at a cost of £85,000.

READ: Sativa Investments to open first of three cannabidiol wellness centres in Bath

The company also announced that it plans to change its name to Sativa Group to reflect its reclassification as a trading company instead of an investment vehicle.

It said it believes the reclassification will “broaden the appeal of the equity opportunity to additional institutions and family offices, many of which are precluded from investing in fund-type vehicles”.

Chief executive and founder Geremy Thomas said: "Sativa delivered on its listing objectives expeditiously and is now into its next phase of becoming a full-spectrum group covering the key value-add parts of the medicinal cannabis and CBD industries.”

Sativa Investments began trading on the NEX Exchange in March 2018 as the UK's first medicinal cannabis investment vehicle.

Shareholders will vote on the proposed name change at the upcoming annual general meeting. 

Following the faster-than-expected legalisation of medicinal cannabis in the UK late last year, Sativa has changed its strategy to focus more on British operations.

Sativa already owns two UK-based businesses, a cannabidiol (CBD) manufacturer, wholesaler and retailer George Botanicals and testing facility PhytoVista Laboratories.

Last week the group announced that it plans to open its first Goodbody & Blunt retail wellness centre in early summer. 

 

]]>
Wed, 08 May 2019 08:03:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219857/uk-cannabis-firm-sativa-investments-proposes-name-change-as-it-unveils-new-strategy-219857.html
<![CDATA[News - Sativa Investments to open first of three cannabidiol wellness centres in Bath ]]> https://www.proactiveinvestors.co.uk/companies/news/219561/sativa-investments-to-open-first-of-three-cannabidiol-wellness-centres-in-bath-219561.html Sativa Investments PLC (NEX:SATI) is to open its first Goodbody & Blunt cannabidiol (CBD) wellness centre in Bath.

The UK medicinal cannabis investment vehicle said the store will include a café for customers to consume CBD infused tea, coffee and water.

READ: Sativa Investments teams up with King's College London to research cannabinoids for medicinal use

Customers will be able to buy CBD sports energy shots and take home CBD coffee beans and tea bags.

The store will stock cannabis products from its George Botanicals business and other brands from around the world.

The group said it has leased a 60.67 square metre retail unit with frontage on the Broad Street and Milson Place City-centre shopping destinations. 

The store is expected to open in early summer.

It is the first of three pilot stores that Sativa intends to open before rolling out a national franchise network.

"Sativa was first to market as a UK-quoted medical cannabis investment vehicle and continues to lead the way with its seed to consumer strategy,” said chief executive Geremy Thomas.

“Goodbody & Blunt's high-street CBD outlets will break with tradition, delivering high-end wellness centres with fully trained staff to advise on the quality and provenance of products.” 

Sativa said every item stocked in the Goodbody & Blunt stores will have passed rigorous industry-leading tests, conducted by its own PhytoVista Laboratories.

CBD is a compound found in the cannabis plant that is non-psychoactive and can be well tolerated, as opposed to tetrahydrocannabinol (THC) – the psychoactive cannabinoid that gets a user “high”.

For this reason, the substance can be sold in the UK without a licence so long as it is not marketed as a medicinal product. CBD is widely available at retailers as an oil, spray or food supplement.

]]>
Thu, 02 May 2019 09:36:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219561/sativa-investments-to-open-first-of-three-cannabidiol-wellness-centres-in-bath-219561.html
<![CDATA[News - London emerges as new hot spot for medicinal cannabis firms to list after UK relaxes rules ]]> https://www.proactiveinvestors.co.uk/companies/news/219176/london-emerges-as-new-hot-spot-for-medicinal-cannabis-firms-to-list-after-uk-relaxes-rules-219176.html A batch of medicinal cannabis firms look set to exploit London’s deep-pocketed investors with stock market listings this year and the flurry of activity is expected to continue. 

The legalisation of medicinal cannabis in the UK last November has seen London emerge as a new hub for companies to list.

READ: Medicinal cannabis: UK remains behind the curve despite new legislation

Canaccord Genuity analyst,  Alex Brooks, told Proactive Investors: “We are working very hard to get a number of companies listed in London …we anticipate that there will be several that we have listed by the end of this year.”

Medicinal cannabis IPOs expected 

European Cannabis Holdings is among the medical cannabis firms understood to be eyeing a stock market listing this year.

The company has so far raised £6mln from investors and is expected to use a London float to support the development of three medicinal cannabis clinics in the UK.

Kanabo Research is reportedly another medicinal company with plans to list in the UK.

The Israeli company, which has developed a vaporiser medical device called VapePod that allows people to inhale cannabis oils, is expected to float on London’s main market by summer.

Medicinal cannabis firm Jacana, founded by Jamaican businesswoman Alexandra Chong, is also said to be mulling an initial public offering on London’s junior market AIM.

Chong, who previously ran the Lulu dating app and is married to Sir Richard Branson's nephew Jack Brockway, has a 100-acre farm in Jamaica and plans to sell medicinal cannabis in North America, Europe and the UK.

London-listed firms expanding into cannabis 

Outside the medicinal cannabis space, there are companies already listed in London that are dipping their toes in the sector.   

Oil and gas firm Highlands Natural Resources PLC (LON:HNR), which trades on the main market, has raised £1.3mln to set up a cannabis operation in Colorado.

READ: Highlands Natural Resources to enter cannabidiol market in Colorado with new growing operation

The new venture, Zoetic Organics, will grow hemp and sell products such as organic hemp oil.

Imperial X, listed on the NEX exchange, plans to launch a cannabis business after its mining investment firm failed.

The firm will join Sativa Investments PLC (NEX:SAT), which is also on the NEX exchange.

Sativa became the UK’s first cannabis investment vehicle to float when it listed last March and its shares have doubled in value since.  

It is currently the only pure-play medicinal cannabis company listed in London but that is about to change, Brooks said.

“It is my judgment that by the end of this year there will be half a dozen listed cannabis companies in London of meaningful scale and that we would be involved in a good chunk of them,” he said.

“That’s just the beginning because if you look at all of these companies they are all relatively conservative cannabis plays … they are very medicinally focused, and there is a lot more scope for the industry beyond just that and there is huge scope for volume growth in the short and medium term.”

Brooks thinks Europe is in the early stages of a growth industry as there is a “very meaningful” end market with a “meaningful set of companies”.

Cannabis the new bitcoin?

Companies that list in London will be hoping to emulate the success seen in Canada, where valuations have surged. 

There has been a rapid rise of cannabis companies in Canada since the country legalised recreational cannabis last October.

Some critics have drawn comparisons to the boom of bitcoin, which has experienced extreme price volatility.  

"There's a belief that it’s all a bubble and it’s all going to end, which is not at all consistent with what the market is doing with these stocks," Brooks said.

]]>
Fri, 26 Apr 2019 11:05:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/219176/london-emerges-as-new-hot-spot-for-medicinal-cannabis-firms-to-list-after-uk-relaxes-rules-219176.html
<![CDATA[News - Sativa Investments teams up with King's College London to research cannabinoids for medicinal use ]]> https://www.proactiveinvestors.co.uk/companies/news/217734/sativa-investments-teams-up-with-king-s-college-london-to-research-cannabinoids-for-medicinal-use-217734.html UK medicinal cannabis investor Sativa Investments PLC (NEX: SATI) has teamed up with King's College London to research the impact of cannabinoids on inflammation and respiratory diseases. 

Under the research agreement, Sativa will supply the university with specific strains of cannabis plants that contain various combinations of the spectrum of at least 113 known cannabinoids, subject to regulatory approval.

READ: Sativa Investments completes 1000th cannabinoid and terpenes test at PhytoVista facility

Sativa will provide the service through investee business, Canada-based Veritas Pharma Inc, and its own on-site testing facility, PhytoVista Laboratories.

Professor Clive Page OBE PhD Professor of Pharmacology at King's College London will lead the research.

"With the UK catching up fast in terms of recognising the benefits of medicinal cannabis, in-country research from the globally-recognised King's College London will assist the medical profession, Government and Regulators in their deliberations,” said Sativa founder and chief executive, Geremy Thomas.

"As the UK's first medicinal cannabis investment vehicle, Sativa remains at the forefront of this fast-developing sector, which effectively mirrors what has been happening in North America since medicinal cannabis was first legalised in Canada in 2001, more than 17 years ago.”

]]>
Tue, 02 Apr 2019 08:27:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/217734/sativa-investments-teams-up-with-king-s-college-london-to-research-cannabinoids-for-medicinal-use-217734.html
<![CDATA[News - Sativa Investments capitalises on first-mover advantage in UK medicinal cannabis ]]> https://www.proactiveinvestors.co.uk/companies/news/217782/sativa-investments-capitalises-on-first-mover-advantage-in-uk-medicinal-cannabis-217782.html  

What Sativa Investments does:

Sativa Investments PLC (NEX:SATI) is Britain's first medicinal cannabis investment vehicle and is now an operating company with two fully trading UK businesses.

Listed on the NEX exchange in March 2018, Sativa was set up to make investments into Canada-based cannabis companies where the drug is now approved for medicinal and recreational use. 

Since the legalisation of medicinal cannabis in the UK in late 2018, Sativa has capitalised on its first-mover advantage to become a seed-to-consumer medicinal cannabis and cannabidiol (CBD) wellness business. 

It is now focused on the sourcing of raw material, advanced extraction, manufacture, testing, distribution, and research & development of cannabis products.

What Sativa Investments owns:

Sativa’s investments include: Canada-based pharmaceutical firm, Veritas Pharma Inc.; Canada pharma-tech business, Rapid Dose Therapeutics Inc., which owns the QuickStrip oral dissolving cannabis strips; and a 60% stake in a joint venture with Germany's Lexamed GmbH.

Its two operating subsidaries are testing facility, PhytoVista Laboratories, and George Botanicals, which develops, manufactures and distributes low-Tetrahydrocannabinol (THC) and CBD wellness products.

Inflexion points: Sativa Investments announced in May that it plans to change its name to Sativa Group to reflect its reclassification as a trading company instead of an investment vehicle. Shareholders will vote on the proposal at the annual general meeting on June 12.  Last month Sativa decided to abandon a plan to grow its own cannabis at a 7.5-acre Wiltshire site. The company believes sourcing raw material will provide greater returns than growing its own supply. Sativa has signed commercial offtake agreements with two suppliers of cannabis oil for the manufacture of CBD products in the UK. These suppliers are Swiss firm, Alponics, and Portuguese cannabis oil supplier, MeridianTulip – Empresa Medicinal Lda. Sativa turned a gross profit of £110,000 and a turnover of £260,000 in 2018 – its first year as a listed company.  The group is planning to open its first of three Goodbody & Blunt wellness centre in Bath on June 28. The centre will sell a range of white label CBD products made by George Botanicals and other suppliers, all of which will be tested by Phytovista. Sativa has teamed up with King's College London to research the impact of CBDs on inflammation and respiratory diseases. Under the research agreement, Sativa will supply the university with specific strains of cannabis plants that contain various combinations of the spectrum of at least 113 known CBDs, subject to regulatory approval. What the CEO says: 

Geremy Thomas, founder and chief executive of Sativa, said in the group's 2018 results: "Sativa has delivered expeditiously on its investment promise to the market and is now recognised as a trading business, with two fully owned UK subsidiaries already performing well.

"This early stage traction within the marketplace proves the group's ability to deliver revenue-generating operations that benefit from first-mover advantage.

"The medicinal cannabis and CBD industries are highly complex and the twelve months of global research that I undertook before Saiva joined the NEX exchange is paying off. "

]]>
Tue, 02 Apr 2019 06:51:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/217782/sativa-investments-capitalises-on-first-mover-advantage-in-uk-medicinal-cannabis-217782.html
<![CDATA[News - Sativa Investments completes 1000th cannabinoid and terpenes test at PhytoVista facility ]]> https://www.proactiveinvestors.co.uk/companies/news/216908/sativa-investments-completes-1000th-cannabinoid-and-terpenes-test-at-phytovista-facility-216908.html Sativa Investments PLC (LON:SATI) has completed its 1000th test of cannabinoid and terpenes at its on-site PhytoVista testing laboratory.

Cannabinoids are a class of around 113 compounds found in cannabis plants and include its medicinal component cannabidiol (CBD) and the psychoactive chemical tetrahydrocannabinol (THC).

READ: Sativa Investments brings inexpert to aid its move into the CBD veterinary market

Terpenes are essential oils extracted from the cannabis plant that can enhance the effects of its various cannabinoids, with most of them also carrying anti-pain or anti-inflammatory benefits.

The cannabis investment firm said increased growth of the CBD industry in the UK had led to a rise in demand for testing and batch certifications, of which PhytoVista is a leading service provider.

The laboratory is designed to test and certify that products and samples conform to regulation and is believed to be the only CBD-focused facility in the UK. Sativa said the lab is aiming to test medicinal cannabis products once it has a handling licence granted by the Home Office.

The company added that it had recruited an analytical chemist and a microbiologist at the lab to help expand capacity while its chief scientific officer, Nick Clarkson, was developing new testing methods while the firm sought accreditation of ISO 17025, which regulates the competency of laboratories.

PhytoVista already operates with an ISO 17025 accreditation.

Geremy Thomas, founder and chief executive of Sativa, said the 1000th test was “an early milestone” in the company’s “holistic seed-to-consumer strategy”, with PhytoVista "a key part of Sativa's internal strategic development as having an in-house, on-site testing facility is assisting the Company's Home Office Research Licence application”.

“The laboratory is also attracting significant interest from the pharmaceutical and academic research areas which need an independent testing facility that mandates Good Laboratory Practice to verify and validate their own findings", he added.

The company's shares, which are traded on the NEX exchange, were at 5.9p in late-morning on Thursday.

--Adds share price--

]]>
Thu, 21 Mar 2019 07:38:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/216908/sativa-investments-completes-1000th-cannabinoid-and-terpenes-test-at-phytovista-facility-216908.html
<![CDATA[News - Sativa Investments brings in expert to aid its move into the CBD veterinary market ]]> https://www.proactiveinvestors.co.uk/companies/news/214341/sativa-investments-brings-in-expert-to-aid-its-move-into-the-cbd-veterinary-market-214341.html Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, has appointed veterinary expert Dr Nick Horniman as its new director of regulatory affairs.

Horniman has thirty years' experience in the veterinary industry and spent more than twenty of those running a group of private veterinary practices which he has since sold.

His appointment fits in nicely with Sativa’s move into the veterinary market, which it announced last month.

READ: Sativa unveils ambitious new strategic blue-print

As part of his new senior management role, Horniman’s job will be to explore the use of cannabis-based treatments in animals.

He will also be tasked with liaising with the relevant agencies to establish CBD regulation and progress Sativa's medicinal cannabis Growing Licence application.

“As announced in [January], Sativa is planning to enter the potentially lucrative CBD veterinary market through Sativa Veterinary services,” said Sativa chief executive Geremy Thomas.

“The CBD veterinary market has already taken off in North America and Dr Horniman will also advise on how best to go about launching the veterinary arm in the UK.

Horniman has been granted options over 3.1mln shares in the company with an exercise of 6.5p per share.

Sativa shares closed at 5.25p on Friday afternoon.

]]>
Mon, 11 Feb 2019 08:00:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/214341/sativa-investments-brings-in-expert-to-aid-its-move-into-the-cbd-veterinary-market-214341.html
<![CDATA[News - Sativa Investments appoints head of new retail arm ]]> https://www.proactiveinvestors.co.uk/companies/news/212572/sativa-investments-appoints-head-of-new-retail-arm-212572.html Sativa Investments PLC (NEX:SATI) has appointed Chris Jones to launch wellness centres that will sell a medicinal range of cannabis-derived products.

Retail professional Jones most recently held the role of consultant sales director at a vaping company with 110 outlets and worked with another in Northern Ireland with 20 stores.

WATCH: Sativa Investments 'at the forefront' of developing UK medical cannabis market

Before that, he had senior positions in the mobile phone industry with names such as Nokia, where he was UK sales director, Dextra Mobile Accessories and Phones 4U. 

Jones, who will be the managing director of Sativa Wellness Centres Limited, helped build Swindon-based mobile service provider Cellular Operations to a subscriber base of 500,000 before it was acquired by Vodafone.

“Chris' experience of growing businesses in these highly competitive markets, coupled with very strong retail and franchise operational knowledge, is an ideal fit for Sativa's aggressive market development plans for its Goodbody & Blunt wellness centres,” said founder and chief executive Geremy Thomas.

“The model will be proofed with two to three retail outlets, then the company has the option to roll it out further or as a franchise.”

CBD products 

The aforementioned Goodbody & Blunt will offer customers a variety of cannabidiol, or CBD wellness products at drop-in cafes.

CBD is a cannabis compound that is thought to have significant medical benefits, but does not make people feel “stoned”.

The fact that CBD-rich cannabis is non-psychoactive or less psychoactive than THC-dominant strains makes it an appealing option for people looking for relief from inflammation, pain and anxiety.

Earlier this month, NEX-listed Sativa, which was set up as a vehicle to invest in medicinal cannabis, announced plans to become a first-mover seed-to-consumer business here in the UK, following the model pioneered in Canada.

Its blueprint will require at least £12mln of funding – which would cover the cost of a glasshouse operation in Wiltshire – and probably more if it is to fully bankroll its ambitious plans.

In afternoon trading, Sativa Investments shares on the NEX market were trading at a mid-price of 5.875p each, up from Monday's close of 5.65p.

 -- Adds share price --

]]>
Tue, 15 Jan 2019 08:04:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/212572/sativa-investments-appoints-head-of-new-retail-arm-212572.html
<![CDATA[Media files - Sativa Investments 'at the forefront' of developing UK medical cannabis market ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/11775/sativa-investments--at-the-forefront--of-developing-uk-medical-cannabis-market-11775.html Thu, 10 Jan 2019 13:55:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/11775/sativa-investments--at-the-forefront--of-developing-uk-medical-cannabis-market-11775.html <![CDATA[News - Sativa Investments unveils ambitious new strategic blue-print ]]> https://www.proactiveinvestors.co.uk/companies/news/212117/sativa-investments-unveils-ambitious-new-strategic-blue-print-212117.html Sativa Investments PLC (LON:SATI), the NEX-based medical cannabis investor, has unveiled plans to become a first-mover seed-to-consumer business in the UK.

Its blueprint will require at least £12mln of funding – which would cover the cost of a glasshouse operation in Wiltshire – and probably more if it is to fully bankroll its ambitious blueprint.

READ: Sativa Investments' investee firm Rapid Dose Therapeutics begins trading on CSE

Sativa is taking its cue from Canada, which first approved the drug for medical use 18 years ago, and is now home to vertically integrated cannabis giants such as Canopy Growth (now listed in New York and worth just shy of US$10bn).

Also revealed in the strategic update was the company’s desire to advance its venture with Lexamed of Germany to provide a distribution channel for its medicinal cannabis and cannabinol, or CBD products.

Wellness retail centres

Also under consideration, are CBD wellness retail centres and clinics and the group will assess the potential veterinary use of the ‘herb’.

Sativa said there had been a change of sentiment in the UK towards the industry from the regulators, government and the medical profession.

There is a growing belief among these groups that the drug may have a role to play in areas such as pain relief that avoids the use of addictive opioids.  

Hemp success

“The company's operations now cover seed growing, in so far as the company has already successfully grown a hemp crop under the CEO's own growers' licence, and along with great strides in developing its medical cannabis business, and has researched, tested, marketed and sold CBD products,” explained Geremy Thomas, Sativa’s founder and chief executive.

"Sativa now has a solid base on which to build its seed-to-consumer model and this next round of fundraising will allow institutions and other investors to participate in what is expected to be a major UK industry."

Listed on the NEX exchange less than nine months ago, Sativa was set up to make investments into Canada-based or dual-listed cannabis companies.

It has so far ploughed cash into six early-stage businesses, including Veritas Pharma and George Botanicals.

]]>
Tue, 08 Jan 2019 07:50:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/212117/sativa-investments-unveils-ambitious-new-strategic-blue-print-212117.html
<![CDATA[News - Sativa Investments' investee firm Rapid Dose Therapeutics begins trading on CSE ]]> https://www.proactiveinvestors.co.uk/companies/news/211376/sativa-investments--investee-firm-rapid-dose-therapeutics-begins-trading-on-cse-211376.html Bio-technology firm Rapid Dose Therapeutics Inc (CSE:DOSE), an investee business of medicinal cannabis investor Sativa Investments PLC (LON:SATI), has been admitted to trading on the Canadian Stock Exchange.

Sativa Investments, which is the UK’s first medicinal cannabis investment firm, subscribed for 400,000 shares at C$50 each in Rapid Dose Therapeutics for C$200,000 in cash ahead of the listing on Monday.

At the close on Monday, shares were trading hands at C$0.85 each.

WATCH: Sativa Investments 'at the forefront' of developing UK medical cannabis market

Rapid Dose Therapeutics has developed a fast-dissolving medicinal cannabis strip, called Quickstrip, that is placed on or under the tongue, or inside the cheek. The company also sells pharmaceuticals, emulsified oils and over-the-counter medicines across North America.

The firm has made an initial paper profit of C$140,000 for Savita Investments, an increase of 70%, after just seven months.

"RDT's technology has very positive implications for both Sativa's medicinal cannabis business and its CBD (cannabidiol) focused 100% subsidiary George Botanicals Limited, and we look forward to continued collaboration with RDT alongside our investment." 

]]>
Tue, 18 Dec 2018 07:29:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211376/sativa-investments--investee-firm-rapid-dose-therapeutics-begins-trading-on-cse-211376.html
<![CDATA[News - Award-winning pain consultant appointed to Sativa Investments’ advisory board ]]> https://www.proactiveinvestors.co.uk/companies/news/210650/award-winning-pain-consultant-appointed-to-sativa-investments-advisory-board-210650.html Sativa Investments PLC (NEX:SATI) has appointed an award-winning pain medicine and anaesthetic consultant to its medical cannabis advisory board.

Matthew Brown is a consultant at the Royal Marsden hospital in West London and recently published research into using cannabinoids for cancer pain treatment.

READ: Sativa announces £3.75mln equity raise

Last month, the UK government gave doctors the green light to prescribe cannabis products to patients for the first time ever.

“The new Home Office guidelines determining the prescription of Medicinal Cannabis encompass the treatment of pain and nausea in cancer patients,” said founder and chief executive Geremy Thomas.

“Matthew's qualifications and research in this area add even further to the input of Sativa's top-level Medicinal Cannabis Advisory Board. Patient outcome is the clear driver in the highly sensitive and prevalent area of cancer treatment.”

]]>
Thu, 06 Dec 2018 08:37:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/210650/award-winning-pain-consultant-appointed-to-sativa-investments-advisory-board-210650.html
<![CDATA[News - Sativa's George Botanicals division expands range of CBD products ]]> https://www.proactiveinvestors.co.uk/companies/news/210106/sativa-s-george-botanicals-division-expands-range-of-cbd-products-210106.html George Botanicals, the CBD products maker owned by Sativa Investments PLC (LON:SATI) has launched a balm and expanded its range of drinkable oils infused with the cannabinoid extract.

Demand for CBD products is growing due to their perceived health and well-being benefits that include pain and stress relief.

READ: Sativa Investments announces £3.75mln equity raise and plans to build UK cannabis greenhouse

The new balm contains one per cent of CBD, while the MCT oils have a five per cent concentration of CBD and derive from coconut oil, making it easy to mix with beverages and soft drinks. 

Natural CBD products are thought to boost internal cannabinoids in a similar way to vitamin supplements. 

MCT oils can also be placed under the tongue for instant flavour and fast absorption.

George Thomas, managing director, said: "CBD has become increasingly popular in the past few months as customers become aware of its associated health and well-being benefits.

The balm will retail for £24.99 and the MCT oils for £29.99.

Nex-listed Sativa acquired George Botanicals in June for £415,000.

]]>
Wed, 28 Nov 2018 08:41:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/210106/sativa-s-george-botanicals-division-expands-range-of-cbd-products-210106.html
<![CDATA[News - Sativa Investments announces £3.75mln equity raise and plans to build UK cannabis greenhouse ]]> https://www.proactiveinvestors.co.uk/companies/news/207381/sativa-investments-announces-375mln-equity-raise-and-plans-to-build-uk-cannabis-greenhouse-207381.html UK medicinal cannabis investment vehicle Sativa Investments PLC (LON:SATI) said it has raised £3.75mln in a share placing and signed heads of terms for a £85,000 option to lease a 7.53 acre development site in Wiltshire.  

The company said it placed 62.5mln new ordinary shares at 6p each and the proceeds of the equity raise would be used to “further Sativa’s progress and development as the UK’s first medicinal cannabis investment vehicle”.

READ: Sativa Investments moves into Germany, one of Europe’s largest medical cannabis markets

Sativa expects the option agreement on the Wiltshire site to be signed today after which it plans to construct a glasshouse on up to 6.86 acres. The site will be used to grow cannabis plants for the production of medicinal cannabis and cannabidiol (CBD) products. An extraction facility and offices will also be built on the site.

The group has been granted planning permission to build the glasshouse. It will enter into a 25-year term lease for the site and will be able to extend this for a further three months for a £15,000 payment under an option that can be exercised at any time up to July 2019.  

Sativa on track to become UK's first seed to consumer medicinal cannabis business

The move is part of the company’s plans to become the UK’s first seed to consumer medicinal cannabis business. Sativa already has a cannabis-testing laboratory in the UK, called PhytoVista Laboratories, and its subsidiary George Botanicals has a UK hemp growers' licence.

Sativa said the cost of the 7.53-acre site, including the construction of the glasshouse, an extraction facility and offices, is estimated to be £10.5mln.

READ: Medicinal cannabis investor Sativa Investments reports 'significant progress' post IPO Sativa to offer products at 'highly competitive rates'

The glasshouse will sit beside an existing 3.6MW capacity bio-digester plant from which the company will be able to purchase electricity at significantly below market rates. This will make it the first green-powered medicinal cannabis canopy in the UK.

“The directors believe that this in turn will enable Sativa to offer products to the market at highly competitive rates,” the company said.

The company said about 194,224 sq ft or 65% of the 298,806 sq ft glasshouse will be harvested while the rest will be used for ancillary space including walkways and seedlings.

Industry figures show that each square foot of canopy produces 40 grams of raw cannabis, which had an average wholesale gross revenue of £4.00 per gram in the last year.

Canadian-based Veritas Pharma Inc. is advising Sativa on cannabis strain selection.

As part of the consideration for the option, Sativa will offer owners of the farm an option to acquire 2 million ordinary shares in the company at a price of 5 pence per share after the development is completed and operational. 

The announcement comes after the UK government said doctors will be able to prescribe medicinal cannabis from November 1.

READ: Recreational pot: Where in the world is it legal and will the UK ever approve?

People suffering from chronic pain, epilepsy, or nausea as a result of chemotherapy or multiple sclerosis (MS) will be among the first to be prescribed the drugs.

]]>
Thu, 18 Oct 2018 12:57:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/207381/sativa-investments-announces-375mln-equity-raise-and-plans-to-build-uk-cannabis-greenhouse-207381.html
<![CDATA[News - Medical cannabis to be available in UK on prescription by start of November ]]> https://www.proactiveinvestors.co.uk/companies/news/206609/medical-cannabis-to-be-available-in-uk-on-prescription-by-start-of-november-206609.html Medicinal cannabis products, used in the treatment of various conditions that cause chronic pain, will be available on prescription to patients from the start of next month following a rescheduling of the drug by UK Home Secretary Sajid Javid.

People suffering from chronic pain, epilepsy, or nausea as a result of chemotherapy or multiple sclerosis (MS) will be among the first to be prescribed the drugs, which marks a turning point in the push to legalise cannabis products in the UK.

READ: Medicinal cannabis investor Sativa Investments reports 'significant progress' post IPO

At the moment, cannabis-derived can only be prescribed in exceptional circumstances after permission is granted by a panel of medical experts, although the Home Office will relax the rules from 1 November.

The policy change follows an incident in June when 12-year old Billy Caldwell had his cannabis oil, prescribed to alleviate the symptoms of epilepsy, confiscated at Heathrow Airport, a decision that was only reversed when an emergency permit was issued by the government.

However, Geremy Thomas, chief executive and founder of medical cannabis company Sativa Investments PLC (NEX:SATI) said last week that the move by the government is not an indicator that the legalisation of recreational marijuana is in the offing.

Instead, Thomas says things will “become clearer” regarding the details of how the medical cannabis industry in the UK will take shape.

He adds that existing manufacturers outside the UK will likely be awarded limited export licenses for medical cannabis products, with investors “becoming more aware” of the scale of the industry.

“[Investors] will recognise that we [the UK] will be a very significant cannabis market,” he says.

]]>
Mon, 08 Oct 2018 15:39:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/206609/medical-cannabis-to-be-available-in-uk-on-prescription-by-start-of-november-206609.html
<![CDATA[News - Medicinal cannabis investor Sativa Investments reports 'significant progress' post IPO ]]> https://www.proactiveinvestors.co.uk/companies/news/205851/medicinal-cannabis-investor-sativa-investments-reports-significant-progress-post-ipo-205851.html Sativa Investments PLC (NEX:SATI), the UK’s first medicinal cannabis investment vehicle, said it has “progressed significantly” since it began trading on the NEX Exchange earlier this year.

The firm raised £1.1mln net of expenses in its initial public offering on March 29 and secured a further £500,000 in June from the LF Miton UK Smaller Companies Fund, its first major institutional investor. Founder and chief executive, Geremy Thomas, and his family invested £560,000 in the company in January. 

In the six months ended June 30, the group has invested £656,000 into Veritas Pharma Inc, Rapid Dose Therapeutics Inc and George Botanicals Ltd.

READ: Sativa Investment moves into Germany, one of Europe’s largest medical cannabis markets

As a newly established investment vehicle, Sativa generated consolidated revenues of £7,700 for the period, reflecting six days of sales by George Botanicals from its acquisition on June 22. Since the period end to August 31, George Botanicals' revenues stood at £68,200.

The group ended the first half with total consolidated assets of £2.08mln and cash at bank and cash equivalents of £1.42mln. Gross profit came to £6,700. 

In July, the company bought UK testing laboratory, PhytoVista Laboratories Ltd, for £460,000. Sativa said the acquisition will allow it meet the need for regulatory and batch testing of cannabidiol (CBD) products and, once approved by the UK Home Office, medicinal cannabis treatments including tetrahydrocannabinol (THC).

Last week Sativa said it had entered into a joint venture with German-based Lexamed GmbH ("Lexamed"), forming a new German medicinal cannabis company named Sativa Germany GmbH ("Sativa Germany"), which will secure German wholesale, import and export licences for the distribution of medicinal cannabis products.

"Sativa has progressed significantly since listing, along with the industry itself, witnessing a sea-change in attitude from the medical profession and also the government in relation to unmet patient needs and widespread realisation that the UK is falling behind in terms of accepting the benefits of medicinal cannabis,” said Thomas.

"The company continues to build a solid foundation for the end-to-end supply of medical cannabis and CBD products to fulfil its seed to consumer strategy." 

Looking ahead, Sativa expects to benefit from being the UK’s first medicinal cannabis investment vehicle as the market develops.

]]>
Thu, 27 Sep 2018 09:44:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205851/medicinal-cannabis-investor-sativa-investments-reports-significant-progress-post-ipo-205851.html
<![CDATA[News - Sativa Investments moves into Germany, one of Europe’s largest medical cannabis markets ]]> https://www.proactiveinvestors.co.uk/companies/news/205398/sativa-investments-moves-into-germany-one-of-europes-largest-medical-cannabis-markets-205398.html Cannabis investment vehicle Sativa Investments PLC (NEX:SATI) is moving into Germany as it looks to exploit the growing demand for cannabinoid products in the country.

Germany is one of the largest medical cannabis markets in Europe following the government’s decision to approve its use by prescription last year.

READ: Sativa positions itself for ‘huge opportunity’ in medicinal cannabis

Sativa has formed a joint venture with Germany-based Lexamed which will secure German wholesale, import and export licences for the distribution of medicinal cannabis products.

The long-term plan is for the products sold by the newly established Sativa Germany to be supplied by Sativa’s UK arm.

That is subject to the company successfully applying for a Home Office Medicinal Cannabis licence, so for the time being the joint venture will source products from any jurisdiction where it is regulatorily accepted.

A Sativa office is being set up in Stuttgart which will sell CBD products supplied by its subsidiary, George Botanicals.

Sative is initially investing €80,000 into the joint venture, which will give it a 60% majority shareholding. This figure could rise up to €250,000 once the German licence has been granted.

‘Important step’

“Initially, Sativa Germany has secured office space in Stuttgart and are actively recruiting sales staff to exploit the growing demand for CBD products in Germany,” said chief executive and founder Geremy Thomas.

“Once regulatory compliances are met, Sativa will supply top quality medicinal cannabis products to the German market.”

He added: “This is an important step for the Company, as it allows an entry point into the key German market to help continue its seed to consumer strategy.”

]]>
Fri, 21 Sep 2018 07:24:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/205398/sativa-investments-moves-into-germany-one-of-europes-largest-medical-cannabis-markets-205398.html
<![CDATA[News - Sativa Investments decides the time is right to appoint a full-time finance head ]]> https://www.proactiveinvestors.co.uk/companies/news/203874/sativa-investments-decides-the-time-is-right-to-appoint-a-full-time-finance-head-203874.html Sativa Investments PLC (LON:SATI), the UK's first medicinal cannabis investment vehicle, has appointed former WPP man Joseph Colliver as its chief financial officer.

Colliver is a qualified chartered accountant with significant management consulting experience. Before joining Sativa, Joseph was a director of consulting at Kantar Consulting, which is part of marketing and advertising leviathan WPP.

READ: Sativa Investments inks IP deal with Canada's Veritas Pharma​

"Joseph brings a depth of international experience including from his time at Kantar Consulting, part of WPP PLC, where he advised clients on developing commercial capability,” said Geremy Thomas, the founder and chief executive officer of Sativa.

“Coupled with his experience as chief financial officer at Kantar Futures, a consultancy business with a US$32 million turnover, his role as global commercial director of WPP's Kantar subsidiary Taylor Nelson Sofres, a US$1.8 billion turnover marketing agency, and his Mazars' Accountancy training, Joseph has a lot to offer the ever-expanding Sativa," Thomas said.

Thomas said that, with four investments under its belt thus far and a pipeline of potential investments, it was time for Sativa to appoint “an experienced, strategically-thinking full-time finance head”.


 

]]>
Thu, 30 Aug 2018 10:01:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/203874/sativa-investments-decides-the-time-is-right-to-appoint-a-full-time-finance-head-203874.html
<![CDATA[News - Sativa Investments inks IP deal with Canada's Veritas Pharma ]]> https://www.proactiveinvestors.co.uk/companies/news/200826/sativa-investments-inks-ip-deal-with-canada-s-veritas-pharma-200826.html Sativa Investments PLC (NEX:SATI) said it has signed an IP sharing agreement with Canada’s Veritas Pharma Inc, which it hopes will help its efforts in the UK’s emerging cannabis market.

The company said it will use Veritas’ cannabis strain lead selection to assist its application to the Home Office Drugs Licensing and Compliance Unit for a medicinal cannabis growing licence.

READ: Sativa Investments refines Orderly Market Agreements to improve liquidity for NEX traded shares

In May, Sativa invested C$200,000 in Veritas.

Chief executive, Geremy Thomas, said: "A key part of Sativa's strategy is to target overseas investments that can be leveraged to assist the company commercially as it participates in the industry in the UK and wider Europe.

“In this case, Veritas' scientific knowledge of seed selection will expedite a potential UK licence application to enable Sativa to grow cannabis strains for its own research and development purposes including use by recipients of grants awarded by the Sativa Foundation."

]]>
Mon, 16 Jul 2018 07:59:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/200826/sativa-investments-inks-ip-deal-with-canada-s-veritas-pharma-200826.html
<![CDATA[News - Sativa Investments refines Orderly Market Agreements to improve liquidity for NEX traded shares ]]> https://www.proactiveinvestors.co.uk/companies/news/200300/sativa-investments-refines-orderly-market-agreements-to-improve-liquidity-for-nex-traded-shares-200300.html Sativa Investments PLC (NEX: SATI) has moved to improve liquidity in its NEX-listed stock by agreeing to a refinement of the Orderly Market Agreements entered into at the time of its float at the end of March.

The group, the UK's first medicinal cannabis investment vehicle, said it has made the move because it is “aware of the exceptional and growing demand amongst investors to own shares in the Company.”

READ: Sativa Investments buys UK medicinal cannabis lab for £435K

All investors who subscribed for Sativa’s ordinary shares in the company at admission entered into an Orderly Market Agreement and the group’s directors of Sativa agreed, should demand arise, to exercise their allocated options and sell the resulting ordinary shares through its corporate adviser and broker, Peterhouse Capital Limited.

However, given the unprecedented demand in the market for its shares, and the desire of Sativa’s directors not to have to be the sole suppliers of stock at levels which its board believes do not reflect the long-term value of the company, it has agreed that all shareholders who are subject to the current Orderly Market Agreements will be permitted to trade in the stock.

The firm added that such trading on the NEX Exchange Growth Market will require the consent of Peterhouse, although it added such consent should not “be unreasonably withheld”.

Sativa said its directors remain subject to the Lock-In Agreements entered into on admission, but they will no longer be required to make further shares available through the exercise of their options.

]]>
Fri, 06 Jul 2018 15:09:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/200300/sativa-investments-refines-orderly-market-agreements-to-improve-liquidity-for-nex-traded-shares-200300.html
<![CDATA[Media files - Sativa Investments PLC acquires UK-based PhytoVista Laboratories ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/9768/sativa-investments-plc-acquires-uk-based-phytovista-laboratories-9768.html Tue, 03 Jul 2018 15:50:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/9768/sativa-investments-plc-acquires-uk-based-phytovista-laboratories-9768.html <![CDATA[News - Sativa Investments buys UK medicinal cannabis lab for £435K ]]> https://www.proactiveinvestors.co.uk/companies/news/200048/sativa-investments-buys-uk-medicinal-cannabis-lab-for-435k-200048.html Sativa Investments PLC (NEX:SATI) has agreed to buy PhytoVista Laboratories, a UK-based lab that tests cannabis oils and hemp products, for £435,000.

The British medicinal cannabis investment vehicle will pay £235,000 in cash and £200,000 worth of shares at 0.04p per share to buy PhytoVista from Carbon Managers Limited.

READ: Sativa Investments positions itself for 'huge opportunity' in medicinal cannabis

Carbon is wholly owned by Sativa’s chief executive Geremy Thomas but he was not involved in the decision-making for the deal.

Sativa independent directors Noel Lyons and Mark Blower assessed the deal and consulted Dr. Stuart Ungar, who is a member of the company's medicinal cannabis advisory board.

Sativa said the purchase price was well below the market value of the assets and equipment acquired. If purchased new, the equipment laboratory would cost more than £580,000, the company said.

“Every batch of medicinal cannabis including CBD oil requires stringent testing, including for cannabinoids, pesticides, heavy metals and mycotoxins, along with full testing for terpenes, residual solvents and microbiology,” Blower said.

“PhytoVista provides a UK-based laboratory facility available to all jurisdictions already testing CBD products commercially, and of course able to service the UK market if and when regulatory changes hit the UK too."

PhytoVista has preferred partner status to the UK's Cannabis Trades Association for batch testing of medicinal cannabis products.

]]>
Tue, 03 Jul 2018 13:01:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/200048/sativa-investments-buys-uk-medicinal-cannabis-lab-for-435k-200048.html
<![CDATA[News - Sativa Investments positions itself for 'huge opportunity' in medicinal cannabis ]]> https://www.proactiveinvestors.co.uk/companies/news/198184/sativa-investments-positions-itself-for-huge-opportunity-in-medicinal-cannabis-198184.html Britain’s medicinal cannabis market can be larger than Canada’s if laws here change believes Geremy Thomas, chief executive of Sativa Investments PLC (LON:SATI).

At present, there is a virtual ban in the UK on any product containing Tetrahydrocannabinol or THC, the substance in marijuana/cannabis that makes you high.

WATCH: Sativa Investments has "unique" market position for UK cannabis investors

But it is a combination of THC and CBD, a pain reliever also derived from marijuana and that is legal in the UK, which gives medicinal cannabis its potency says Thomas.

In Canada, which legalised medicinal products in 2001, sales are predicted to soar to C$10bn (£5.8bn).

There are almost twice as many people in the UK so it’s fair to see the market here being considerably larger, Thomas told Proactive.

Germany is another example. Laws were relaxed in March and by June medicinal prescriptions had jumped to 5,000 per month.

“A lot of people are getting benefit from the component parts of cannabis restricted in the UK because of political campaigns in the seventies.

“Why should our [UK] patients be denied access to something that is proving to be very effective around the world.

“The market is racing away in North America and on our doorstep in Germany.”

And that’s the point of Sativa.

Shift in opinion

Initially, it will give UK investors a way into the North American markets but ultimately Thomas wants to establish a first mover position if the UK legal position changes.

Thomas is convinced there will be a change in the law, albeit it might take up to two years.

Public opinion has shifted, he says. 

High profile cases such as six year-old epileptic Alfie Dingley, whose mother had to go the Netherlands to get a cannabis oil that dramatically improved his condition, are driving a change in mood.

Thomas, a serial entrepreneur, admits his interest is financial rather than compassionate and points to a track record of being ahead of the game in his previous ventures.

His first fortune was in mobile phones just as cellular took off.

That was followed by a shift into telecoms ahead of the dot.com boom and most recently a move into consumer finance that benefited from a regulatory crackdown.

That business, George Banco, was sold for £53mln last year.

A conference in Vancouver convinced Thomas that medicinal cannabis was the place to make his next fortune.

“I was blown away by the scale and size of the investment,” he says.

Sativa a way in

EU laws prohibit direct investment into overseas companies where the operations are technically illegal within the investor’s own country, but through a vehicle such as Sativa there is a route in.

NEX-listed, the company raised £1.6mln when it went public, most of which came from Thomas himself and friends and family.

The company has made two small investments so far: Veritas a Toronto-based firm which is carrying out testing to find the optimum combinations of CBD/THC for specific ailments.

Rapid Dose Therapeutics, meanwhile, has adapted dissolving film technology to deliver cannabis oils accurately, quicker and more effectively.

Sativa is likely to assume the rights to distribute Rapid Dose’s products in the UK and Europe.

The company has invested C$200,000 in both companies, while there is a memorandum of understanding in place for a 51% stake in George Botanicals, a UK-based CBD business owned by Carbon Managers, another of Thomas’s vehicles.

While these investments are small, Thomas is not short of ambition for the company and cites UK-based but Nasdaq-listed GW Pharma, which has a market value of US$4bn.

GW is reportedly close to US approval for a cannabis-based childhood epilepsy drug Epidolex, which it might launch in Europe next year.

Spreading the word

If successful it will raise awareness of the market even more though Thomas believes a major part of his role at Sativa is to educate both the marketplace and investors about the benefits of medicinal cannabis.

It’s a role he clearly relishes.

Unlike opiates, for instance, cannabis oils deliver real benefits to patients and without doing damage to them in the process.

People written off by traditional medicines have also seen dramatic turnarounds on cannabis oil.

“The opportunity in this space is huge and the driver is that medicinal cannabis works.”

 

]]>
Mon, 04 Jun 2018 11:03:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/198184/sativa-investments-positions-itself-for-huge-opportunity-in-medicinal-cannabis-198184.html
<![CDATA[Media files - Sativa Investments has "unique" market position for UK cannabis investors ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/9359/sativa-investments-has-unique-market-position-for-uk-cannabis-investors-9359.html Wed, 23 May 2018 12:09:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/9359/sativa-investments-has-unique-market-position-for-uk-cannabis-investors-9359.html <![CDATA[News - Sativa invests in Canadian medicinal cannabis group Veritas Pharma ]]> https://www.proactiveinvestors.co.uk/companies/news/197349/sativa-invests-in-canadian-medicinal-cannabis-group-veritas-pharma-197349.html Sativa Investments PLC (NEX:SATI) has subscribed for half a million shares in Veritas Pharma Inc (OTCMKTS:VRTHF), an emerging Canadian pharma company specialising in medicinal cannabis therapies.

The NEX-listed medicinal cannabis investment vehicle said it had subscribed for 500,000 new shares at C$0.4 per share, a total cost of C$0.2mln in cash.

WATCH: Sativa Investments has "unique" market position for UK cannabis investors

The firm said Veritas Pharma focuses on the discovery, product development and commercialisation of effective patented Medicinal Cannabis therapies which target disease conditions in the areas of chronic pain, senior long-term and palliative care.

Sativa added that Veritas, through its subsidiary company, Cannevert Therapeutics Ltd., was aiming to obtain compelling scientific evidence for healthcare professionals to utilise medicinal cannabis strains with a reliable therapeutic effect on patients.

Geremy Thomas, Sativa chief executive, said: "We are delighted to increase our portfolio of investments by, in this case, adding a pharmaceutical research and development business.

Veritas Pharma is a well-respected company in the medicinal cannabis sector with an excellent pipeline for the development of strains to treat unmet clinical needs, and is a highly suitable investment."

He added: "The investment in Veritas reflects the Company's strategy to invest in well-established companies in jurisdictions where the use of Medicinal Cannabis is regulatory accepted. Canada approved the use of medicinal cannabis in 2001."

]]>
Mon, 21 May 2018 07:57:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/197349/sativa-invests-in-canadian-medicinal-cannabis-group-veritas-pharma-197349.html